Evidence map›Paper›PMID 42688949›Full record

ReviewFrontiers in medicine2026

Chronic thromboembolic pulmonary hypertension: towards an etiology-oriented conceptual framework.

Masayuki Nishiyama, Takayuki Okada, Wakana Teranaka, Takahiko Naruko, Tadaaki Koyama

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masayuki NishiyamaDepartment of Cardiovascular Surgery, Kansai Medical University, Osaka, Japan.
Takayuki OkadaDepartment of Cardiovascular Surgery, Kansai Medical University, Osaka, Japan.
Wakana TeranakaDepartment of Cardiology, Kansai Medical University Medical Center, Osaka, Japan.
Takahiko NarukoDepartment of Cardiology, Kansai Medical University Medical Center, Osaka, Japan.
Tadaaki KoyamaDepartment of Cardiovascular Surgery, Kansai Medical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is traditionally regarded as a late complication of unresolved acute pulmonary embolism. However, this paradigm is challenged by several observations: up to half of patients lack a documented embolic history, distal or microvascular disease is common, and marked geographic differences in treatment strategies exist. While pulmonary endarterectomy (PEA) predominates in Western centers, Japanese programs have advanced balloon pulmonary angioplasty (BPA), particularly for distal disease. These discrepancies suggest that CTEPH represents a biologically heterogeneous condition rather than a post-embolic entity. Methods and conceptual framework: We developed an etiology-oriented framework integrating pathogenic mechanisms, vascular lesion distribution, and therapeutic strategies. Using Virchow's triad as a structural lens, dominant disease drivers were mapped to distinct phenotypes within a thrombo-vasculopathic spectrum. Results: Five mechanistic phenotypes are proposed: (1) thromboembolism-related (Type Ia), characterized by unresolved embolic obstruction and proximal disease; (2) thrombophilia-associated (Type Ib), driven by systemic hypercoagulability; (3) inflammation- or immune-mediated (Type Ic), associated with endothelial injury and vascular remodeling; (4) structural pulmonary arteriopathy-associated (Type II), in which intrinsic arterial abnormalities precede thrombosis; and (5) idiopathic (Type III), without identifiable cause. These phenotypes form a continuum defined by the relative contributions of thrombotic obstruction and intrinsic vascular remodeling. Within this framework, PEA aligns with proximal disease, whereas BPA and medical therapy correspond to distal vasculopathic phenotypes. Conclusion: CTEPH should be reconsidered as a heterogeneous thrombo-vasculopathic syndrome. An etiology-based framework linking pathobiology, anatomy, and treatment may help explain global practice variation and support phenotype-guided management.

Indexed as

balloon pulmonary angioplastychronic thromboembolic pulmonary hypertensionclassificationpulmonary endarterectomypulmonary hypertension

Identifiers

PMID42688949
PMCPMC13536283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.